{"public_id":"cl_397583a6595e5e403e721963d01baceb","status":"active","superseded_by_public_id":null,"corpus_id":3202878,"text":"Griffithsin (GRFT) showed synergistic activity profile with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C isolates in primary PBMCs and CD4+ MT-4 cells, with combination indices between 0.34 and 0.79 at the EC(95) level.","confidence":0.95,"paper":{"corpus_id":3202878,"title":"Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.","url":"https://sah.borca.ai/papers/3202878"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0cb17d4bda13f983e35f26f144aa18a9","name":"griffithsin","description":"A potent anti-HIV peptide from natural sources evaluated as a topical microbicide component.","types":["peptide","antiviral agent"],"url":"https://sah.borca.ai/concepts/co_0cb17d4bda13f983e35f26f144aa18a9"},{"public_id":"co_2888969919751de2dbd419ec94daa6ea","name":"maraviroc","description":"An antiretroviral drug used in combination with griffithsin against HIV-1.","types":["antiretroviral drug"],"url":"https://sah.borca.ai/concepts/co_2888969919751de2dbd419ec94daa6ea"},{"public_id":"co_2c1ad54e7128cb638ea55c76d0d95111","name":"tenofovir","description":"An antiretroviral drug used in combination with griffithsin against HIV-1.","types":["antiretroviral drug"],"url":"https://sah.borca.ai/concepts/co_2c1ad54e7128cb638ea55c76d0d95111"},{"public_id":"co_58ac6a2917d86f879fb3300c59a56fe2","name":"HIV-1 clade C","description":"A subtype of HIV-1 against which griffithsin combinations were tested in primary PBMCs and CD4+ MT-4 cells.","types":["viral subtype"],"url":"https://sah.borca.ai/concepts/co_58ac6a2917d86f879fb3300c59a56fe2"},{"public_id":"co_88ff3f5b7310f5d581740b652d1b3d2c","name":"enfuvirtide","description":"An antiretroviral drug used in combination with griffithsin against HIV-1.","types":["antiretroviral drug"],"url":"https://sah.borca.ai/concepts/co_88ff3f5b7310f5d581740b652d1b3d2c"},{"public_id":"co_93925334864d4f818eb194e019f177f8","name":"combination indices","description":"Quantitative measures of synergy based on the median effect principle, ranging from 0.34 to 0.79 at the EC(95) level.","types":["metric"],"url":"https://sah.borca.ai/concepts/co_93925334864d4f818eb194e019f177f8"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_397583a6595e5e403e721963d01baceb"}